Neratinib exhibited substantial clinical activity in patients with and without prior trastuzumab treatment [225], while the neratinib plus paclitaxel regimen yielded higher complete pathological response rates than the trastuzumab plus paclitaxel regimen in patients with HER2-positive, HR-negative breast cancer [226]. Here, ERBB2 is linked to breast cancer.